TLR7/8 agonists trigger immunostimulatory properties of human 6-sulfo LacNAc dendritic cells

H Jähnisch, R Wehner, A Tunger, A Kunze, S Oehrl… - Cancer letters, 2013 - Elsevier
Imiquimod and resiquimod represent Toll-like receptor (TLR) 7 and 8 agonists, which
emerged as attractive candidates for tumor therapy. To elucidate immune cells, which mainly …
被引用次数：25 相关文章
[PDF] academia.edu

[PDF][PDF] TLR7/8 agonists trigger immunostimulatory properties of human 6-sulfo LacNAc dendritic cells

H Jähnisch, R Wehner, A Tunger, A Kunze, S Oehrl… - Cancer Letters, 2013 - academia.edu
abstract Imiquimod and resiquimod represent Toll-like receptor (TLR) 7 and 8 agonists,
which emerged as attractive candidates for tumor therapy. To elucidate immune cells, which …

TLR7/8 agonists trigger immunostimulatory properties of human 6-sulfo LacNAc dendritic cells

H Jähnisch, R Wehner, A Tunger, A Kunze… - Cancer …, 2013 - pubmed.ncbi.nlm.nih.gov
Imiquimod and resiquimod represent Toll-like receptor (TLR) 7 and 8 agonists, which
emerged as attractive candidates for tumor therapy. To elucidate immune cells, which mainly …

TLR7/8 agonists trigger immunostimulatory properties of human 6-sulfo LacNAc dendritic cells.

H Jähnisch, R Wehner, A Tunger, A Kunze, S Oehrl… - Cancer Letters, 2013 - europepmc.org
Imiquimod and resiquimod represent Toll-like receptor (TLR) 7 and 8 agonists, which
emerged as attractive candidates for tumor therapy. To elucidate immune cells, which mainly …

TLR7/8 agonists trigger immunostimulatory properties of human 6-sulfo LacNAc dendritic cells

H Jähnisch, R Wehner, A Tunger, A Kunze, S Oehrl… - Cancer Letters, 2013 - infona.pl
Imiquimod and resiquimod represent Toll-like receptor (TLR) 7 and 8 agonists, which
emerged as attractive candidates for tumor therapy. To elucidate immune cells, which mainly …

[引用][C] TLR7/8 agonists trigger immunostimulatory properties of human 6-sulfo LacNAc dendritic cells

H Jähnisch, R Wehner, A Tunger, A Kunze, S Oehrl… - Cancer …, 2013 - Elsevier Limited